Cocaine-seeking behavior in a genetic model of attention-deficit/hyperactivity disorder following adolescent methylphenidate or atomoxetine treatments

Drug and Alcohol Dependence

Volumn 140, Issue , 2014, Pages 25-32

  Jordan, Chloe J ^a   Harvey, Roxann C ^a   Baskin, Britahny B ^a   Dwoskin, Linda P ^b   Kantak, Kathleen M ^a  

^a BOSTON UNIVERSITY   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Addiction; Atomoxetine; Attention deficit hyperactivity disorder; Cocaine; Methylphenidate; Spontaneously Hypertensive Rat

Indexed keywords

ATOMOXETINE; COCAINE; METHYLPHENIDATE; CENTRAL STIMULANT AGENT; PROPYLAMINE;

ADOLESCENT; ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASSOCIATION; ATTENTION DEFICIT DISORDER; COCAINE DEPENDENCE; COMORBIDITY; CONTROLLED STUDY; DRUG SEEKING BEHAVIOR; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; REINFORCEMENT; ANIMAL; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; DRUG EFFECTS; GENETICS; INSTRUMENTAL CONDITIONING; PHYSIOLOGY; PSYCHOLOGY; SPECIES DIFFERENCE; SPONTANEOUSLY HYPERTENSIVE RAT; WISTAR KYOTO RAT; WISTAR RAT;

RATTUS; RODENTIA;

ANIMALS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; COCAINE-RELATED DISORDERS; CONDITIONING, OPERANT; DRUG-SEEKING BEHAVIOR; EXTINCTION, PSYCHOLOGICAL; MALE; METHYLPHENIDATE; PROPYLAMINES; RATS; RATS, INBRED SHR; RATS, INBRED WKY; RATS, WISTAR; SPECIES SPECIFICITY;

EID: 84924839349     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2014.04.020     Document Type: Article

References (54)

1. Achat-Mendes C., Nic Dhonnchadha B.Á., Platt D.M., Kantak K.M., Spealman R.D. Glycine transporter-1 inhibition preceding extinction training inhibits reacquisition of cocaine seeking. Neuropsychopharmacology 2012, 37:2837-2845.
2. Andersen S.L. Stimulants and the developing brain. Trends Pharmacol. Sci. 2005, 26:237-243.
3. Barkley R.A., Fischer M., Smallish L., Fletcher K. Does the treatment of attention-deficit/hyperactivity disorder with stimulants contribute to drug use/abuse?. A 13-year prospective study. Pediatrics 2003, 111:97-109.
4. Biederman J., Wilens T., Mick E., Spencer T., Faraone S.V. Pharmacotherapy of attention-deficit/hyperactivity disorder reduces risk for substance use disorder. Pediatrics 1999, 104:1-5.
5. Bolla K.I., Eldreth D.A., London E.D., Kiehl K.A., Mouratidis M., Contoreggi C., Matochik J.A., Kurian V., Cadet J.L., Kimes A.S., Funderburk F.R., Ernst M. Orbitofrontal cortex dysfunction in abstinent cocaine abusers performing a decision-making task. NeuroImage 2003, 19:1085-1094.
6. Bymaster F.P., Katner J.S., Nelson D.L., Hemrick-Luecke S.K., Threlkeld P.G., Heiligenstein J.H., Morin S.M., Gehlert D.R., Perry K.W. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology 2002, 27:699-711.
7. Chesler E.J., Wilson S.G., Lariviere W.R., Rodriguez-Zas S.L., Mogil J.S. Influences of laboratory environment on behavior. Nat. Neurosci. 2002, 5:1101-1102.
8. Ciccocioppo R., Paolo Sanna P., Weiss F. Cocaine-predictive stimulus induces drug-seeking behavior and neural activation in limbic brain regions after multiple months of abstinence: reversal by D1 antagonists. Proc. Natl. Acad. Sci. U.S.A. 2001, 98:1976-1981.
9. Dalsgaard S., Mortensen P.B., Frydenberg M., Thomsen P.H. ADHD, stimulant treatment in childhood and subsequent substance abuse in adulthood-a naturalistic long-term follow-up study. Addict. Behav. 2014, 39:325-328.
10. Degenhardt L., Chiu W.T., Sampson N., Kessler R.C., Anthony J.C., Angermeyer M., Bruffaerts R., de Girolamo G., Gureje O., Huang Y., Karam A., Kostyuchenko S., Lepine J.P., Mora M.E., Neumark Y., Ormel J.H., Pinto-Meza A., Posada-Villa J., Stein D.J., Takeshima T., Wells J.E. Toward a global view of alcohol, tobacco, cannabis, and cocaine use: findings from the WHO World Health Mental Surveys. PLoS Med. 2008, 5:e141.
11. Di Pietro N.C., Mashhoon Y., Heaney C., Yager L.M., Kantak K.M. Role of dopamine D1 receptors in the prefrontal dorsal agranular insular cortex in mediating cocaine self-administration in rats. Psychopharmacology 2008, 200:81-91.
12. Economidou D., Dalley J.W., Everitt B.J. Selective norepinephrine reuptake inhibition by atomoxetine prevents cue-induced heroin and cocaine seeking. Biol. Psychiatry 2011, 69:266-274.
13. Ghods-Sharifi S., Haluk D.M., Floresco S.B. Differential effects of inactivation of the orbitofrontal cortex on strategy set-shifting and reversal learning. Neurobio. Learn. Mem. 2008, 89:567-573.
14. Gudjonsson G.H., Sigurdsson J.F., Sigfusdottir I.D., Young S. An epidemiological study of ADHD symptoms among young persons and the relationship with cigarette smoking, alcohol consumption, and illicit drug use. J. Child Psychol. Psychiatry 2012, 53:304-312.
15. Grace A.A. Psychostimulant actions on dopamine and limbic system function: relevance to the pathophysiology and treatment of ADHD. Stimulant Drugs and ADHD: Basic and Clinical Neuroscience 2001, 134-157. Oxford University Press, London, United Kingdom. M.V. Solanto, A.F.T. Arnsten, F.X. Castellanos (Eds.).
16. Harvey R.C., Jordan C.J., Tassin D.H., Moody K.R., Dwoskin L.P., Kantak K.M. Performance on a strategy set shifting task during adolescence in a genetic model of attention deficit/hyperactivity disorder: methylphenidate vs. atomoxetine treatments. Behav. Brain Res. 2013, 244:38-47.
17. Harvey R.C., Sen S., Deaciuc A., Dwoskin L.P., Kantak K.M. Methylphenidate treatment in adolescent rats with an attention deficit/hyperactivity disorder phenotype: cocaine addiction vulnerability and dopamine transporter function. Neuropsychopharmacology 2011, 36:837-847.
18. Humphreys K.L., Eng T., Lee S.S. Stimulant medication and substance use outcomes: a meta-analysis. JAMA Psychiatry 2013, 70:740-749.
19. Janak P.H., Bowers M.S., Corbit L.H. Compound stimulus presentation and the norepinephrine reuptake inhibitory atomoxetine enhance long-term extinction of cocaine-seeking behavior. Neuropsychopharmacology 2012, 37:975-985.
20. Kantak K.M., Black Y., Valencia E., Green-Jordan K., Eichenbaum H.B. Dissociable effects of lidocaine inactivation of the rostral and caudal basolateral amygdala on the maintenance and reinstatement of cocaine-seeking behavior in rats. J. Neurosci. 2002, 22:1126-1136.
21. Kantak K.M., Mashhoon Y., Silverman D.N., Janes A.C., Goodrich C.M. Role of the orbitofrontal cortex and dorsal striatum in regulating the dose-related effects of self-administered cocaine. Behav. Brain Res. 2009, 201:128-136.
22. Kantak K.M., Singh T., Kerstetter K.A., Dembro K.A., Mutebi M.M., Harvey R.C., Deschepper C.F., Dwoskin L.P. Advancing the spontaneous hypertensive rat model of attention deficit/hyperactivity disorder. Behav. Neurosci. 2008, 122:340-357.
23. Kratochvil C.J., Heiligenstein J.H., Dittman R., Spencer T.J., Biederman J., Wernicke J., Newcorn J.H., Casat C., Milton D., Michelson D. Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open-label trial. J. Am. Acad. Child Adolesc. Psychiatry 2002, 41:776-784.
24. Kringelbach M.L. The human orbitofrontal cortex: linking reward to hedonic experience. Nat. Rev. Neurosci. 2005, 6:691-702.
25. Kuczenski R., Segal D.S. Exposure of adolescent rats to oral methylphenidate: preferential effects on extracelluar norepinephrine and absence of sensitization and cross-sensitization to methamphetamine. J. Neurosci. 2002, 22:7264-7271.
26. Lambert N.M., Hartsough C.S. Prospective study of tobacco smoking and substance dependencies among samples of ADHD and non-ADHD participants. J. Learn. Disabilities 1998, 31:533-544.
27. Lee S.S., Humphreys K.L., Flory K., Liu R., Glass K. Prospective association of childhood attention-deficit/hyperactivity disorder (ADHD) and substance use and abuse/dependence: a meta-analytic review. Clin. Psychol. Rev. 2011, 31:328-341.
28. Mannuzza S., Klein R.G., Truong N.L., Moulton J.L., Roizen E.R., Howell K.H., Castellanos F.X. Age of methylphenidate treatment initiation in children with ADHD and later substance abuse: prospective follow-up into adulthood. Am. J. Psychiatry 2008, 165:604-609.
29. Martins S., Tramontina S., Polanczyk G., Eizirik M., Swanson J.M., Rohde L.A. Weekend holidays during methylphenidate use in ADHD children: a randomized clinical trial. J. Child Adolesc. Psychopharm. 2004, 14:195-205.
30. Mattiuz E.L., Ponsler G.D., Barbuch R.J., Wood P.G., Mullen J.H., Shugert R.L., Li Q., Wheeler W.J., Kuo F., Conrad P.C., Sauer J.M. Disposition and metabolic fate of atomoxetine hydrochloride: pharmacokinetics, metabolism, and excretion in the Fischer 344 rat and beagle dog. Drug Metab. Dispos. 2003, 31:88-97.
31. McCarthy S., Wilton L., Murray M.L., Hodgkins P., Asherson P., Wong I.C.K. Persistence of pharmacological treatment into adulthood, in UK primary care, for ADHD patients who started treatment in childhood or adolescence. BMC Psychiatry 2012, 12:219-227.
32. Mill J., Sagvolden T., Asherson P. Sequence analysis of Drd2, Drd4, and Dat1 in SHR and WKY rat strains. Behav. Brain Func. 2005, 1:p24.
33. Mitchell J.T., McIntyre E.M., McClernon F.J., Kollins S.H. Smoking motivation in adults with attention-deficit/hyperactivity disorder using the Wisconsin Inventory of Smoking Dependence Motives. Nicotine Tob. Res. 2014, 16:120-125.
34. Nelissen K., Jarraya B., Arsenault J.T., Rosen B.R., Wald L.L., Mandeville J.B., Marota J.J., Vanduffel W. Neural correlates of the formation and retention of cocaine-induced stimulus-reward associations. Biol. Psychiatry 2012, 72:422-428.
35. Roessner V., Sagvolden T., DasBanerjee T., Middleton F.A., Faraone S.V., Walaas S.I., Becker A., Rothenberger A., Bock N. Methylphenidate normalizes elevated dopamine transporter densities in an animal model of the attention-deficit/hyperactivity disorder combined type, but not to the same extent in one of the attention-deficit/hyperactivity disorder inattentive type. Neuroscience 2010, 167:1183-1191.
36. Rubia K., Smith A.B., Halari R., Matsukura F., Mohammad M., Taylor E., Brammer M.J. Disorder-specific dissociation of orbitofrontal dysfunction in boys with pure conduct disorder during reward and ventrolateral prefrontal dysfunction in boys with pure ADHD during sustained attention. Am. J. Psychiatry 2009, 166:83-94.
37. Russell V.A., Sagvolden T., Borgå Johansen E. Animal models of attention-deficit hyperactivity disorder. Behav. Brain Func. 2005, 1:9.
38. Sagvolden T., Russell V.A., Aase H., Johansen E.B., Farshbaf M. Rodent models of attention-deficit/hyperactivity disorder. Biol. Psychiatry 2005, 57:1239-1247.
39. Schenk S., Izenwasser S. Pretreatment with methylphenidate sensitizes rats to the reinforcing effects of cocaine. Pharmacol. Biochem. Behav. 2002, 72:651-657.
40. Schwarz, A., Cohen, S., 2013. A.D.H.D. seen in 11% of U.S. children as diagnoses rise. NY Times. Available at Accessed 12 March 2014. http://www.nytimes.com/2013/04/01/health/more-diagnoses-of-hyperactivity-causing-concern.html.
41. Somkuwar S.S., Darna M., Kantak K.M., Dwoskin L.P. Adolescence methylphenidate treatment in a rodent model of attention deficit/hyperactivity disorder: dopamine transporter function and cellular distribution in adulthood. Biochem. Pharmacol. 2013, 86:309-316.
42. Somkuwar S.S., Jordan C.J., Kantak K.M., Dwoskin L.P. Adolescent atomoxetine treatment in a rodent model of ADHD: effects on cocaine self-administration and dopamine transporters in frontostriatal regions. Neuropsychopharmacology 2013, 38:2588-2597.
43. Spear L.P. The adolescent brain and age-related behavioral manifestations. Neurosci. Biobehav. Rev. 2000, 24:417-463.
44. Sun H., Cocker P.J., Zeeb F.D., Winstanley C.A. Chronic atomoxetine treatment during adolescence decreases impulsive choice, but not impulsive action, in adult rats and alters markers of synaptic plasticity in the orbitofrontal cortex. Psychopharmacology (Berl.) 2012, 219:285-301.
45. Tomie A., Grimes K.L., Poherecky L.A. Behavioral characteristics and neurobiological substrates shared by Pavlovian sign-tracking and drug abuse. Brain Res. Rev. 2008, 58:121-135.
46. Unrod M., Drobes D.J., Stasieqicz P.R., Ditre J.W., Heckman B., Miller R.R., Sutton S.K., Brandon T.H. Decline in cue-provoked craving during cue exposure therapy for smoking cessation. Nicotine Tob. Res. 2013, 16:306-315.
47. van Emmerik-van Oortmerssen K., van de Glind G., van den Brink W., Smit F., Crunelle C.L., Swets M., Schoevers R.A. Prevalence of attention-deficit hyperactivity disorder in substance use disorder patients: a meta-analysis and meta-regression analysis. Drug Alcohol Depend. 2012, 122:11-19.
48. Visser S.N., Bitsko R.H., Danielson M.L., Perou R., Blumberg S.J. Increasing Prevalence of Parent-Reported Attention-Deficit/Hyperactivity Disorder Among Children --- United States, 2003 and 2007. 2010, Center for Disease Control and Prevention, Available at http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5944a3.htm. Accessed 12 March 2014.
49. Wilens T.E., Faraone S.V., Biederman J., Gunawardene S. Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse?. A meta-analytic review of the literature. Pediatrics 2003, 111:179-185.
50. Wilens T.E., Martelon M., Joshi G., Bateman C., Fried R., Petty C., Biederman J. Does ADHD predict substance-use disorders? A 10-year follow-up study of young adults with ADHD. J. Am. Acad. Child Adol. Psychiatry 2011, 50:543-553.
51. Wooters T.E., Bardo M.T. Methylphenidate and fluphenazine, but not amphetamine, differentially affect impulsive choice in Spontaneously Hypertensive, Wistar-Kyoto and Sprague-Dawley rats. Brain Res. 2011, 1396:45-53.
52. Wyss J.M., Kadish I., van Groen T. Age-related decline in spatial learning and memory: attenuation by captopril. Clin. Exp. Hypertension 2003, 25:455-474.
53. Yager L.M., Robinson T.E. A classically conditioned cocaine cue acquires greater control over motivated behavior in rats prone to attribute incentive salience to a food cue. Psychopharmacology 2013, 226:217-228.
54. Zahniser N.R., Sorkin A. Rapid regulation of the dopamine transporter: role in stimulant addiction?. Neuropharmacology 2004, 47:80-91.